⚠ Evidence note: Human outcome data on longevity interventions is limited; most claims rest on surrogate markers or animal models. Nothing here is medical advice.
Denosumab (RANK-Ligand Inhibition)
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-09-18 — RANK-ligand Inhibition to Combat Sarcopenia With Underlying Osteoporosis: Randomized, double-blind, double-dummy active-controlled trial underway testing denosumab for sarcopenia in patients with coexisting osteoporosis — trial registered, no outcomes reported yet (human-rct, protocol stage). [human-rct] (novelty: 3)
Open questions
Related
Contributing findings
RANK-ligand Inhibition to Combat Sarcopenia With Underlying Osteoporosis
18-sep-2026
novelty 3
per-area 3
strengthens